Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral LUM-201 versus placebo in treatment-naive prepubertal children with growth hormone deficiency
2025-523820-26-01Phase 3Authorised
- Sponsor
- Lumos Pharma, Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in growth hormone deficiency (GHD) comparing Ibutamoren mesylate with Placebo (2 arms). Primary endpoint: Annualized height velocity from Day 1 to Month 12. Planned start Oct 2026; status: authorised.
02
Drugs
ibutamoren
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2025-523820-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523820-26-01.